

# A Single Index Model for Longitudinal Outcomes to Optimize Individual Treatment Decision Rules

Lanqiu Yao & Thaddeus Tarpey

NYU School of Medicine

*Department of Population Health*

*Division of Biostatistics*

August 3, 2020

JSM 2020



## Introduction

**Precision Medicine:** Identify the Treatment Decision Rule (TDR) with patient's baseline information.

- ▶ Baseline measures:  $\mathbf{x} = (x_1, \dots, x_p)'$
- ▶ A function  $D$  that assigns a treatment decision to a patient based on  $\mathbf{x} = (x_1, \dots, x_p)'$

$$D : \mathbf{x} \rightarrow T$$

- ▶ A treatment decision:
  - ▶  $T = 1$  for treatment 1
  - ▶  $T = 2$  for treatment 2

## Introduction

**Precision Medicine:** Identify the Treatment Decision Rule (TDR) with patient's baseline information.

- ▶ Baseline measures:  $\mathbf{x} = (x_1, \dots, x_p)'$
- ▶ A function  $D$  that assigns a treatment decision to a patient based on  $\mathbf{x} = (x_1, \dots, x_p)'$

$$D : \mathbf{x} \rightarrow T$$

- ▶ A treatment decision:
  - ▶  $T = 1$  for treatment 1
  - ▶  $T = 2$  for treatment 2

## Introduction

**Precision Medicine:** Identify the Treatment Decision Rule (TDR) with patient's baseline information.

- ▶ Baseline measures:  $\mathbf{x} = (x_1, \dots, x_p)'$
- ▶ A function  $D$  that assigns a treatment decision to a patient based on  $\mathbf{x} = (x_1, \dots, x_p)'$

$$D : \mathbf{x} \rightarrow T$$

- ▶ A treatment decision:
  - ▶  $T = 1$  for treatment 1
  - ▶  $T = 2$  for treatment 2

## Introduction

**Precision Medicine:** Identify the Treatment Decision Rule (TDR) with patient's baseline information.

- ▶ Baseline measures:  $\mathbf{x} = (x_1, \dots, x_p)'$
- ▶ A function  $D$  that assigns a treatment decision to a patient based on  $\mathbf{x} = (x_1, \dots, x_p)'$

$$D : \mathbf{x} \rightarrow T$$

- ▶ A treatment decision:
  - ▶  $T = 1$  for treatment 1
  - ▶  $T = 2$  for treatment 2



## Single index model

### Generated Effect Modifier (GEM) model

Petkova et al (2016, *Biostatistics*)

$$GEM = w = \alpha' \mathbf{x} = \alpha_1 x_1 + \cdots + \alpha_p x_p$$

GEM model ( $k = 2$ ):

$$\begin{cases} y_1 = \gamma_{01} + \gamma_{11} GEM + \epsilon_1 & \text{(Treatment 1)} \\ y_2 = \gamma_{02} + \gamma_{21} GEM + \epsilon_2 & \text{(Treatment 2)} \end{cases}$$

- Choose  $\alpha$  that maximizes the statistical significance of modifying or interaction effect



## Single index model

### Generated Effect Modifier (GEM) model

Petkova et al (2016, *Biostatistics*)

$$GEM = w = \alpha' \mathbf{x} = \alpha_1 x_1 + \cdots + \alpha_p x_p$$

GEM model ( $k = 2$ ):

$$\begin{cases} y_1 = \gamma_{01} + \gamma_{11} GEM + \epsilon_1 & \text{(Treatment 1)} \\ y_2 = \gamma_{02} + \gamma_{21} GEM + \epsilon_2 & \text{(Treatment 2)} \end{cases}$$

- Choose  $\alpha$  that maximizes the statistical significance of modifying or interaction effect



## Single index model

### Generated Effect Modifier (GEM) model

Petkova et al (2016, *Biostatistics*)

$$GEM = w = \alpha' \mathbf{x} = \alpha_1 x_1 + \cdots + \alpha_p x_p$$

GEM model ( $k = 2$ ):

$$\begin{cases} y_1 = \gamma_{01} + \gamma_{11} GEM + \epsilon_1 & \text{(Treatment 1)} \\ y_2 = \gamma_{02} + \gamma_{21} GEM + \epsilon_2 & \text{(Treatment 2)} \end{cases}$$

- Choose  $\alpha$  that maximizes the statistical significance of modifying or interaction effect

## Single index model

### Single index model with multiple links (SIMML) model

Park et al (2019, *JSPI*)

Model:

$$y_k = g_k(\alpha' x) + \epsilon_k$$

where  $g_k$  is a nonlinear link function for treatment  $k$ .

- Non linear link function
- Flexible methods for determining composite variables

## Single index model

### Single index model with multiple links (SIMML) model

Park et al (2019, *JSP*)

Model:

$$y_k = g_k(\alpha' x) + \epsilon_k$$

where  $g_k$  is a nonlinear link function for treatment  $k$ .

- Non linear link function
- Flexible methods for determining composite variables

## Single index model

### Single index model with multiple links (SIMML) model

Park et al (2019, *JSP*)

Model:

$$y_k = g_k(\alpha' x) + \epsilon_k$$

where  $g_k$  is a nonlinear link function for treatment  $k$ .

- Non linear link function
- Flexible methods for determining composite variables

## Motivation Data: EMBARC

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ A multi-site, placebo-controlled randomized clinical trial (RCT)
- ▶ Two treatment arms: Anti-depression ("drug") and placebo
- ▶ 8-week longitudinal trial
- ▶ Hamilton Depression Rating Scale (HDRS)
- ▶ Large collection of baseline measures

## Motivation Data: EMBARC

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ A multi-site, placebo-controlled randomized clinical trial (RCT)
- ▶ Two treatment arms: Anti-depression ("drug") and placebo
- ▶ 8-week longitudinal trial
- ▶ Hamilton Depression Rating Scale (HDRS)
- ▶ Large collection of baseline measures

## Motivation Data: EMBARC

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ A multi-site, placebo-controlled randomized clinical trial (RCT)
- ▶ Two treatment arms: Anti-depression ("drug") and placebo
- ▶ 8-week longitudinal trial
- ▶ Hamilton Depression Rating Scale (HDRS)
- ▶ Large collection of baseline measures

## Motivation Data: EMBARC

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ A multi-site, placebo-controlled randomized clinical trial (RCT)
- ▶ Two treatment arms: Anti-depression ("drug") and placebo
- ▶ 8-week longitudinal trial
- ▶ Hamilton Depression Rating Scale (HDRS)
- ▶ Large collection of baseline measures


## Motivation Data: EMBARC

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)


- ▶ A multi-site, placebo-controlled randomized clinical trial (RCT)
- ▶ Two treatment arms: Anti-depression ("drug") and placebo
- ▶ 8-week longitudinal trial
- ▶ Hamilton Depression Rating Scale (HDRS)
- ▶ Large collection of baseline measures

## Motivation Data: EMBARC


EMBARC Study




## Motivation Data: EMBARC



## Motivation Data: EMBARC




## Motivation Data: EMBARC






## Motivation Data: EMBARC

EMBARC Study




Contour plot of coefficients






# Motivation Data: EMBARC

EMBARC Study




Contour plot of coefficients






## Motivation Data: EMBARC

EMBARC Study




Contour plot of coefficients






# Motivation Data: EMBARC

EMBARC Study



Contour plot of coefficients



Introduction

○  
○○  
○○○

Method

●○○○○○○○

Simulation Study

○○○○○○○○

EMBARC

○○○

Discussion

○○○

# Purity



## Single Index Model for Longitudinal Outcomes

Linear mixed effect model for longitudinal data:

$$y_{ki} = S_i \beta_k + S_i b_{ki} + \epsilon_{ki} \quad (1)$$



## Single Index Model for Longitudinal Outcomes

Linear mixed effect model for longitudinal data:

$$\mathbf{y}_{ki} = \mathbf{S}_i \boldsymbol{\beta}_k + \mathbf{S}_i \mathbf{b}_{ki} + \epsilon_{ki} \quad (1)$$

## Single Index Model for Longitudinal Outcomes

Single index model for longitudinal data:

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_{ki} \mathbf{b}_{ki} + \epsilon_{ki} \quad (2)$$

- $\mathbf{S}_i$  is the design matrix,  $S_{ki} = \begin{pmatrix} 1 & t_1 & t_1^2 \\ \vdots & \vdots & \vdots \\ 1 & t_{n_t} & t_{n_t}^2 \end{pmatrix}_{n_t \times t}$ ;
- $\boldsymbol{\beta}_k$  is the fixed effect coefficients
- $\boldsymbol{\Gamma}_k$  is the fixed effect coefficients
- Biosignature:  $\mathbf{w}_i = \boldsymbol{\alpha}' \mathbf{x}_i$
- $\mathbf{b}_{ki} \sim MVN(0, \mathbf{D}_k)$
- $\epsilon_{ki} \sim MVN(0, \sigma_k^2)$

## Single Index Model for Longitudinal Outcomes

Single index model for longitudinal data:

$$\mathbf{y}_{ki} = \mathbf{S}_i(\beta_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_{ki} \mathbf{b}_{ki} + \epsilon_{ki} \quad (2)$$

- $\mathbf{S}_i$  is the design matrix,  $S_{ki} = \begin{pmatrix} 1 & t_1 & t_1^2 \\ \vdots & \vdots & \vdots \\ 1 & t_{n_t} & t_{n_t}^2 \end{pmatrix}_{n_t \times t}$ ;
- $\beta_k$  is the fixed effect coefficients
- $\boldsymbol{\Gamma}_k$  is the fixed effect coefficients
- Biosignature:  $w_i = \boldsymbol{\alpha}' \mathbf{x}_i$
- $\mathbf{b}_{ki} \sim MVN(0, \mathbf{D}_k)$
- $\epsilon_{ki} \sim MVN(0, \sigma_k^2)$

## Single Index Model for Longitudinal Outcomes

Single index model for longitudinal data:

$$\mathbf{y}_{ki} = \mathbf{S}_i(\beta_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_{ki} \mathbf{b}_{ki} + \epsilon_{ki} \quad (2)$$

- $\mathbf{S}_i$  is the design matrix,  $S_{ki} = \begin{pmatrix} 1 & t_1 & t_1^2 \\ \vdots & \vdots & \vdots \\ 1 & t_{n_t} & t_{n_t}^2 \end{pmatrix}_{n_t \times t}$ ;
- $\beta_k$  is the fixed effect coefficients
- $\boldsymbol{\Gamma}_k$  is the fixed effect coefficients
- Biosignature:  $w_i = \boldsymbol{\alpha}' \mathbf{x}_i$
- $\mathbf{b}_{ki} \sim MVN(0, \mathbf{D}_k)$
- $\epsilon_{ki} \sim MVN(0, \sigma_k^2)$

## Single Index Model for Longitudinal Outcomes

Single index model for longitudinal data:

$$\mathbf{y}_{ki} = \mathbf{S}_i(\beta_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_{ki} \mathbf{b}_{ki} + \epsilon_{ki} \quad (2)$$

- $\mathbf{S}_i$  is the design matrix,  $S_{ki} = \begin{pmatrix} 1 & t_1 & t_1^2 \\ \vdots & \vdots & \vdots \\ 1 & t_{n_t} & t_{n_t}^2 \end{pmatrix}_{n_t \times t}$ ;
- $\beta_k$  is the fixed effect coefficients
- $\boldsymbol{\Gamma}_k$  is the fixed effect coefficients
- Biosignature:  $\mathbf{w}_i = \boldsymbol{\alpha}' \mathbf{x}_i$
- $\mathbf{b}_{ki} \sim MVN(0, \mathbf{D}_k)$
- $\epsilon_{ki} \sim MVN(0, \sigma_k^2)$

## Single Index Model for Longitudinal Outcomes

Single index model for longitudinal data:

$$\mathbf{y}_{ki} = \mathbf{S}_i(\beta_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_{ki} \mathbf{b}_{ki} + \epsilon_{ki} \quad (2)$$

- $\mathbf{S}_i$  is the design matrix,  $S_{ki} = \begin{pmatrix} 1 & t_1 & t_1^2 \\ \vdots & \vdots & \vdots \\ 1 & t_{n_t} & t_{n_t}^2 \end{pmatrix}_{n_t \times t}$ ;
- $\beta_k$  is the fixed effect coefficients
- $\boldsymbol{\Gamma}_k$  is the fixed effect coefficients
- Biosignature:  $\mathbf{w}_i = \boldsymbol{\alpha}' \mathbf{x}_i$
- $\mathbf{b}_{ki} \sim MVN(0, \mathbf{D}_k)$
- $\epsilon_{ki} \sim MVN(0, \sigma_k^2)$

## Single Index Model for Longitudinal Outcomes

**Goal:** Estimate a linear biosignature using baseline measures that optimally separates outcomes from the two treatment groups

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i) + \mathbf{b}_{ki}) + \epsilon_{ki}$$

Coefficients:

$$\mathbf{z}_{ki} = \boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i) + \mathbf{b}_{ki}$$

Distributions of coefficients:

$$\mathbf{z}_{ki} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_k)$$

## Single Index Model for Longitudinal Outcomes

**Goal:** Estimate a linear biosignature using baseline measures that optimally separates outcomes from the two treatment groups

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i) + \mathbf{b}_{ki}) + \epsilon_{ki}$$

Coefficients:

$$\mathbf{z}_{ki} = \boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i) + \mathbf{b}_{ki}$$

Distributions of coefficients:

$$\mathbf{z}_{ki} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_k)$$

## Single Index Model for Longitudinal Outcomes

**Goal:** Estimate a linear biosignature using baseline measures that optimally separates outcomes from the two treatment groups

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i) + \mathbf{b}_{ki}) + \epsilon_{ki}$$

Coefficients:

$$\mathbf{z}_{ki} = \boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i) + \mathbf{b}_{ki}$$

Distributions of coefficients:

$$\mathbf{z}_{ki} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_k + \mathbf{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_k)$$

## Single Index Model for Longitudinal Outcomes

**Goal:** Estimate a linear biosignature using baseline measures that optimally separates outcomes from the two treatment groups

Treatment 1:

$$\mathbf{z}_{1i} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_1 + \boldsymbol{\Gamma}_1(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_1)$$

Treatment 2:

$$\mathbf{z}_{2i} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_2 + \boldsymbol{\Gamma}_2(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_2)$$

The distributions can "move" apart in directions  $\boldsymbol{\Gamma}_k$  as  $\mathbf{w}_i = \boldsymbol{\alpha}' \mathbf{x}_i$  varies.



## Single Index Model for Longitudinal Outcomes

**Goal:** Estimate a linear biosignature using baseline measures that optimally separates outcomes from the two treatment groups

Treatment 1:

$$\mathbf{z}_{1i} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_1 + \mathbf{\Gamma}_1(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_1)$$

Treatment 2:

$$\mathbf{z}_{2i} | \mathbf{x}_i \sim MVN(\boldsymbol{\beta}_2 + \mathbf{\Gamma}_2(\boldsymbol{\alpha}' \mathbf{x}_i), \mathbf{D}_2)$$

The distributions can "move" apart in directions  $\mathbf{\Gamma}_k$  as  $\mathbf{w}_i = \boldsymbol{\alpha}' \mathbf{x}_i$  varies.



## Kullback-Leibler divergence

KL divergence

$$D_{KL}(F_1 || F_2) = \int_{-\infty}^{+\infty} f_1(x) \log\left(\frac{f_1(x)}{f_2(x)}\right) dx$$

where  $f_1$  and  $f_2$  denote the probability density of  $F_1$  and  $F_2$ .

It has properties:

- ▶ The Non-negative;
- ▶ Measure of how far the distribution  $F_1$  is from the distribution  $F_2$ .

## Kullback-Leibler divergence

### KL divergence

$$D_{KL}(F_1 || F_2) = \int_{-\infty}^{+\infty} f_1(x) \log\left(\frac{f_1(x)}{f_2(x)}\right) dx$$

where  $f_1$  and  $f_2$  denote the probability density of  $F_1$  and  $F_2$ .

It has properties:

- ▶ The Non-negative;
- ▶ Measure of how far the distribution  $F_1$  is from the distribution  $F_2$ .

## Kullback-Leibler divergence

### KL divergence

$$D_{KL}(F_1 || F_2) = \int_{-\infty}^{+\infty} f_1(x) \log\left(\frac{f_1(x)}{f_2(x)}\right) dx$$

where  $f_1$  and  $f_2$  denote the probability density of  $F_1$  and  $F_2$ .

It has properties:

- ▶ The Non-negative;
- ▶ Measure of how far the distribution  $F_1$  is from the distribution  $F_2$ .

# Purity

## Individual Purity

$$g(\alpha' \mathbf{x}) = D_{KL}(F_1 || F_2)(\alpha' \mathbf{x}) + D_{KL}(F_2 || F_1)(\alpha' \mathbf{x}) \quad (3)$$

## Dataset Purity

$$G(\alpha) = E(g(\alpha' \mathbf{x})) = A_0 + A_1 \mu'_x \alpha + A_2 \alpha' (\Sigma_x + \mu_x \mu'_x) \alpha \quad (4)$$

where

- ▶  $A_0 = -q + \frac{1}{2} \text{tr}(\mathbf{D}_2^{-1} \mathbf{D}_1) + \frac{1}{2} \text{tr}(\mathbf{D}_1^{-1} \mathbf{D}_2) + \frac{1}{2} (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\beta_1 - \beta_2)$
- ▶  $A_1 = (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$
- ▶  $A_2 = \frac{1}{2} (\Gamma_1 - \Gamma_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$

# Purity

## Individual Purity

$$g(\alpha' \mathbf{x}) = D_{KL}(F_1 || F_2)(\alpha' \mathbf{x}) + D_{KL}(F_2 || F_1)(\alpha' \mathbf{x}) \quad (3)$$

## Dataset Purity

$$G(\alpha) = E(g(\alpha' \mathbf{x})) = A_0 + A_1 \mu'_x \alpha + A_2 \alpha' (\Sigma_x + \mu_x \mu'_x) \alpha \quad (4)$$

where

- ▶  $A_0 = -q + \frac{1}{2} \text{tr}(\mathbf{D}_2^{-1} \mathbf{D}_1) + \frac{1}{2} \text{tr}(\mathbf{D}_1^{-1} \mathbf{D}_2) + \frac{1}{2} (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\beta_1 - \beta_2)$
- ▶  $A_1 = (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$
- ▶  $A_2 = \frac{1}{2} (\Gamma_1 - \Gamma_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$

# Purity

## Individual Purity

$$g(\alpha' \mathbf{x}) = D_{KL}(F_1 || F_2)(\alpha' \mathbf{x}) + D_{KL}(F_2 || F_1)(\alpha' \mathbf{x}) \quad (3)$$

## Dataset Purity

$$G(\alpha) = E(g(\alpha' \mathbf{x})) = A_0 + A_1 \mu'_x \alpha + A_2 \alpha' (\Sigma_x + \mu_x \mu'_x) \alpha \quad (4)$$

where

- ▶  $A_0 = -q + \frac{1}{2} \text{tr}(\mathbf{D}_2^{-1} \mathbf{D}_1) + \frac{1}{2} \text{tr}(\mathbf{D}_1^{-1} \mathbf{D}_2) + \frac{1}{2} (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\beta_1 - \beta_2)$
- ▶  $A_1 = (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$
- ▶  $A_2 = \frac{1}{2} (\Gamma_1 - \Gamma_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$

# Purity

## Individual Purity

$$g(\alpha' \mathbf{x}) = D_{KL}(F_1 || F_2)(\alpha' \mathbf{x}) + D_{KL}(F_2 || F_1)(\alpha' \mathbf{x}) \quad (3)$$

## Dataset Purity

$$G(\alpha) = E(g(\alpha' \mathbf{x})) = A_0 + A_1 \mu'_x \alpha + A_2 \alpha' (\Sigma_x + \mu_x \mu'_x) \alpha \quad (4)$$

where

- ▶  $A_0 = -q + \frac{1}{2} \text{tr}(\mathbf{D}_2^{-1} \mathbf{D}_1) + \frac{1}{2} \text{tr}(\mathbf{D}_1^{-1} \mathbf{D}_2) + \frac{1}{2} (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\beta_1 - \beta_2)$
- ▶  $A_1 = (\beta_1 - \beta_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$
- ▶  $A_2 = \frac{1}{2} (\Gamma_1 - \Gamma_2)' (\mathbf{D}_1^{-1} + \mathbf{D}_2^{-1}) (\Gamma_1 - \Gamma_2)$

## Algorithm

- ▶ 0: Initial an  $\alpha$
- ▶ 1: Fit the longitudinal single index models

$$\mathbf{Y}_{ki} = \mathbf{S}_i(\beta_k + \mathbf{b}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \epsilon_{ki}, k = \{1, 2\}$$

- ▶ 2: Estimate  $\hat{\beta}_1, \hat{\beta}_2, \hat{\boldsymbol{\Gamma}}_1, \hat{\boldsymbol{\Gamma}}_2, \hat{\mathbf{D}}_1, \hat{\mathbf{D}}_2$
- ▶ 3: Calculate purity based on the function

$$G(\boldsymbol{\alpha}) = \hat{A}_0 + \hat{A}_1 \hat{\mu}'_x \boldsymbol{\alpha} + \hat{A}_2 \boldsymbol{\alpha}' (\hat{\Sigma}_x + \hat{\mu}_x \hat{\mu}'_x) \boldsymbol{\alpha}$$

- ▶ 4: Obtain  $\hat{\boldsymbol{\alpha}}^*$  that maximizes the purity function

$$\hat{\boldsymbol{\alpha}}^* = \arg \max_{\boldsymbol{\alpha}} G(\boldsymbol{\alpha})$$

- ▶ 5: Fit LME and calculate  $\hat{\beta}_1^*, \hat{\beta}_2^*, \hat{\boldsymbol{\Gamma}}_1^*, \hat{\boldsymbol{\Gamma}}_2^*, \hat{\mathbf{D}}_1^*, \hat{\mathbf{D}}_2^*$  for treatment decision rule calculation.

## Simulation

### Outcome generation function

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_i \mathbf{b}_{ki} + \boldsymbol{\epsilon}_{ki}$$

- ▶ Treatment group:  $k = 2$ ;
- ▶ Number of subjects in group  $k$ :  $n_k = 100$ ;  $N = \sum_k n_k$
- ▶ Design matrix:  $\mathbf{S}_i = [ 1 \ t \ t^2 ]$ ,  $t = (0, 1, 2, 3, 4, 6, 8)'$
- ▶ Fixed effect:  $\boldsymbol{\beta}_1 = (0 \ 1 \ 0.1)'$ ,  $\boldsymbol{\beta}_2 = (0 \ 0.9 \ 0.1)'$
- ▶ Random effect:  $\mathbf{b}_{ki} \sim MVN(0, D_k)$

$$\mathbf{D}_1 = \begin{pmatrix} 1 & 0 & 0 \\ 0 & 1 & 0 \\ 0 & 0 & 2 \end{pmatrix}, \mathbf{D}_2 = \begin{pmatrix} 1 & 0 & 0 \\ 0 & 1 & 0.5 \\ 0 & 0.5 & 1 \end{pmatrix}$$

## Simulation

### Outcome generation function

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_i \mathbf{b}_{ki} + \epsilon_{ki}$$

- ▶ Treatment group:  $k = 2$ ;
- ▶ Number of subjects in group  $k$ :  $n_k = 100$ ;  $N = \sum_k n_k$
- ▶ Design matrix:  $\mathbf{S}_i = [ \mathbf{1} \quad \mathbf{t} \quad \mathbf{t}^2 ]$ ,  $\mathbf{t} = (0, 1, 2, 3, 4, 6, 8)'$
- ▶ Fixed effect:  $\boldsymbol{\beta}_1 = (0 \quad 1 \quad 0.1)'$ ,  $\boldsymbol{\beta}_2 = (0 \quad 0.9 \quad 0.1)'$
- ▶ Random effect:  $\mathbf{b}_{ki} \sim MVN(0, D_k)$

- ▶  $D_1 = \begin{pmatrix} 1 & 0 & 0 \\ 0 & 1 & 0 \\ 0 & 0 & 2 \end{pmatrix}$ ,  $D_2 = \begin{pmatrix} 1 & 0 & 0 \\ 0 & 1 & 0.5 \\ 0 & 0.5 & 1 \end{pmatrix}$

## Simulation

### Outcome generation function

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_i \mathbf{b}_{ki} + \epsilon_{ki}$$

- ▶  $\boldsymbol{\Gamma}_1 = (0 \ 1 \ 0)'$ ,  $\boldsymbol{\Gamma}_2 = (0 \ \cos(\theta) \ \sin(\theta))'$ ;
- ▶  $\theta : \{0^\circ, 60^\circ, 120^\circ, 180^\circ\}$
- ▶ Covariates:  $\mathbf{x}_i \sim MVN(0, \Sigma_x)$
- ▶  $\Sigma_x$ : equal correlation matrix, correlation = 0.5
- ▶ Dimension of predictors:  $p = 2, 4, 8, 16$
- ▶ Random error:  $\sigma_k = 1, 2, 10$
- ▶ Simulated 1000 data sets

## Simulation

### Outcome generation function

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_i \mathbf{b}_{ki} + \epsilon_{ki}$$

- ▶  $\boldsymbol{\Gamma}_1 = ( \begin{array}{ccc} 0 & 1 & 0 \end{array} )'$ ,  $\boldsymbol{\Gamma}_2 = ( \begin{array}{ccc} 0 & \cos(\theta) & \sin(\theta) \end{array} )'$ ;
- ▶  $\theta : \{0^\circ, 60^\circ, 120^\circ, 180^\circ\}$
- ▶ Covariates:  $\mathbf{x}_i \sim MVN(0, \Sigma_x)$
- ▶  $\Sigma_x$ : equal correlation matrix, correlation = 0.5
- ▶ Dimension of predictors:  $p = 2, 4, 8, 16$
- ▶ Random error:  $\sigma_k = 1, 2, 10$
- ▶ Simulated 1000 data sets

## Simulation

### Outcome generation function

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_i \mathbf{b}_{ki} + \epsilon_{ki}$$

- ▶  $\boldsymbol{\Gamma}_1 = (0 \ 1 \ 0)'$ ,  $\boldsymbol{\Gamma}_2 = (0 \ \cos(\theta) \ \sin(\theta))'$ ;
- ▶  $\theta : \{0^\circ, 60^\circ, 120^\circ, 180^\circ\}$
- ▶ Covariates:  $\mathbf{x}_i \sim MVN(0, \Sigma_x)$
- ▶  $\Sigma_x$ : equal correlation matrix, correlation = 0.5
- ▶ Dimension of predictors:  $p = 2, 4, 8, 16$
- ▶ Random error:  $\sigma_k = 1, 2, 10$
- ▶ Simulated 1000 data sets

## Simulation

### Outcome generation function

$$\mathbf{y}_{ki} = \mathbf{S}_i(\boldsymbol{\beta}_k + \boldsymbol{\Gamma}_k(\boldsymbol{\alpha}' \mathbf{x}_i)) + \mathbf{S}_i \mathbf{b}_{ki} + \epsilon_{ki}$$

- ▶  $\boldsymbol{\Gamma}_1 = ( \begin{array}{ccc} 0 & 1 & 0 \end{array} )'$ ,  $\boldsymbol{\Gamma}_2 = ( \begin{array}{ccc} 0 & \cos(\theta) & \sin(\theta) \end{array} )'$ ;
- ▶  $\theta : \{0^\circ, 60^\circ, 120^\circ, 180^\circ\}$
- ▶ Covariates:  $\mathbf{x}_i \sim MVN(0, \Sigma_x)$
- ▶  $\Sigma_x$ : equal correlation matrix, correlation = 0.5
- ▶ Dimension of predictors:  $p = 2, 4, 8, 16$
- ▶ Random error:  $\sigma_k = 1, 2, 10$
- ▶ Simulated 1000 data sets

## Proportion of correct decision (PCD)

Average change scores:

$$U_{ki} = \frac{Y_{ki}(t = 8) - Y_{ki}(t = 0)}{8 - 0}$$

Treatment decision rule (TDR):

$$D(\alpha' x_i) = I(U_{1i} > U_{2i}) + 1 = \begin{cases} 1 & \text{Treatment 1} \\ 2 & \text{Treatment 2} \end{cases}$$

## Proportion of correct decision (PCD)

Average change scores:

$$U_{ki} = \frac{Y_{ki}(t = 8) - Y_{ki}(t = 0)}{8 - 0}$$

Treatment decision rule (TDR):

$$D(\alpha' x_i) = I(U_{1i} > U_{2i}) + 1 = \begin{cases} 1 & \text{Treatment 1} \\ 2 & \text{Treatment 2} \end{cases}$$

## Proportion of correct decision (PCD)

Outcome:

$$\hat{\mathbf{Y}}_{ki} = \mathbf{S}_i(\hat{\boldsymbol{\beta}}_k + \hat{\boldsymbol{\Gamma}}_k(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i))$$

Treatment decision rule (TDR):

$$D(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i) = I(\hat{U}_{1i} > \hat{U}_{2i}) + 1 = \begin{cases} 1 & \text{Treatment 1} \\ 2 & \text{Treatment 2} \end{cases}$$

Criterion: Proportion of correct decision (PCD)

$$PCD = \frac{\sum_{i=1}^{n_1+n_2} I(D(\boldsymbol{\alpha}' \mathbf{x}_i) = D(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i))}{n_1 + n_2}$$

## Proportion of correct decision (PCD)

Outcome:

$$\hat{\mathbf{Y}}_{ki} = \mathbf{S}_i(\hat{\boldsymbol{\beta}}_k + \hat{\boldsymbol{\Gamma}}_k(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i))$$

Treatment decision rule (TDR):

$$D(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i) = I(\hat{U}_{1i} > \hat{U}_{2i}) + 1 = \begin{cases} 1 & \text{Treatment 1} \\ 2 & \text{Treatment 2} \end{cases}$$

Criterion: Proportion of correct decision (PCD)

$$PCD = \frac{\sum_{i=1}^{n_1+n_2} I(D(\boldsymbol{\alpha}' \mathbf{x}_i) = D(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i))}{n_1 + n_2}$$

## Proportion of correct decision (PCD)

Outcome:

$$\hat{\mathbf{Y}}_{ki} = \mathbf{S}_i(\hat{\boldsymbol{\beta}}_k + \hat{\boldsymbol{\Gamma}}_k(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i))$$

Treatment decision rule (TDR):

$$D(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i) = I(\hat{U}_{1i} > \hat{U}_{2i}) + 1 = \begin{cases} 1 & \text{Treatment 1} \\ 2 & \text{Treatment 2} \end{cases}$$

Criterion: Proportion of correct decision (PCD)


$$PCD = \frac{\sum_{i=1}^{n_1+n_2} I(D(\boldsymbol{\alpha}' \mathbf{x}_i) = D(\hat{\boldsymbol{\alpha}}' \mathbf{x}_i))}{n_1 + n_2}$$

# Simulation

## Approaches:

- ▶ Longitudinal single index model (Longitudinal-SI)
- ▶ Linear generated effect modifier model (Linear-GEM)
- ▶ Single index model with multiple links model (SIMML)

## Simulation: Proportion of correct decision (PCD)



Introduction

○  
○○  
○○○

Method

○○○○○○○○

Simulation Study

○○○○○●○

EMBARC

○○○

Discussion

○○○

## Simulation: Contour plots



Introduction

○  
○○  
○○○

Method

○○○○○○○○

Simulation Study

○○○○○○●

EMBARC

○○○

Discussion

○○○

## Simulation: Contour plots



# EMBARC

## Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ 58 subjects in placebo group, 45 subjects in treatment group
- ▶ Covariates: Demographics, Behavior measure, Cortical thickness
- ▶ 13 covariates were selected by stepwise selection.

# EMBARC

## Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ 58 subjects in placebo group, 45 subjects in treatment group
- ▶ Covariates: Demographics, Behavior measure, Cortical thickness
- ▶ 13 covariates were selected by stepwise selection.

# EMBARC

## Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ 58 subjects in placebo group, 45 subjects in treatment group
- ▶ Covariates: Demographics, Behavior measure, Cortical thickness
- ▶ 13 covariates were selected by stepwise selection.

# EMBARC

## Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

- ▶ 58 subjects in placebo group, 45 subjects in treatment group
- ▶ Covariates: Demographics, Behavior measure, Cortical thickness
- ▶ 13 covariates were selected by stepwise selection.

# EMBARC

- ▶ Average change scores:

$$U_i = \frac{Y_i(t=8) - Y_i(t=0)}{8 - 0}$$

- ▶ Treatment decision rule ?
- ▶ Performance measure: The "value" ( $V$ ) of treatment decision rule  $D$ :

$$V(D) = E_{\mathbf{x}}(E_{U|\mathbf{x}}(U|\mathbf{x}, T = D(\boldsymbol{\alpha}' \mathbf{x}))$$

- ▶ Estimation: Inverse Probability Weighted Estimator (IPWE)

$$\widehat{V(D)} = \sum_{i=1}^{n_1+n_2} U_i I(T_i = D(\widehat{\boldsymbol{\alpha}}' \mathbf{x}_i)) / \sum_{i=1}^{n_1+n_2} I(T_i = D(\widehat{\boldsymbol{\alpha}}' \mathbf{x}_i))$$

# EMBARC

- ▶ Average change scores:

$$U_i = \frac{Y_i(t=8) - Y_i(t=0)}{8 - 0}$$

- ▶ Treatment decision rule ?
- ▶ Performance measure: The "value" ( $V$ ) of treatment decision rule  $D$ :

$$V(D) = E_{\mathbf{x}}(E_{U|\mathbf{x}}(U|\mathbf{x}, T = D(\boldsymbol{\alpha}' \mathbf{x}))$$

- ▶ Estimation: Inverse Probability Weighted Estimator (IPWE)

$$\widehat{V(D)} = \sum_{i=1}^{n_1+n_2} U_i I(T_i = D(\widehat{\boldsymbol{\alpha}}' \mathbf{x}_i)) / \sum_{i=1}^{n_1+n_2} I(T_i = D(\widehat{\boldsymbol{\alpha}}' \mathbf{x}_i))$$

# EMBARC

- ▶ Average change scores:


$$U_i = \frac{Y_i(t=8) - Y_i(t=0)}{8 - 0}$$

- ▶ Treatment decision rule ?
- ▶ Performance measure: The "value" ( $V$ ) of treatment decision rule  $D$ :

$$V(D) = E_{\mathbf{x}}(E_{U|\mathbf{x}}(U|\mathbf{x}, T = D(\boldsymbol{\alpha}' \mathbf{x}))$$

- ▶ Estimation: Inverse Probability Weighted Estimator (IPWE)

$$\widehat{V(D)} = \sum_{i=1}^{n_1+n_2} U_i I(T_i = D(\widehat{\boldsymbol{\alpha}}' \mathbf{x}_i)) / \sum_{i=1}^{n_1+n_2} I(T_i = D(\widehat{\boldsymbol{\alpha}}' \mathbf{x}_i))$$

**EMBARC****Estimated value of treatment decision rules**

## Discussion

- ▶ **Longitudinal Single Index model:** Combine baseline characteristics into a single index in the context of linear mixed effect model
- ▶ **Simulation:** Good estimation of Proportion of correction decision (PCD) in simulation study
- ▶ **EMBARC** Similar performance as SIMML, less variance.
- ▶ **Future work:** Variable selection, Hypothesis test,...

# Reference

- ▶ Bock, HH, (2003), Convexity-based clustering criteria: theory, algorithms, and applications in statistics," Statistical Methods Applications, 12, 293-317.
- ▶ Park, H., Petkova, E., Ogden, RT, and Tarpey, T., (2020), A Single-index model with multiple-links," to appear Journal of Statistical Planning and Inference.
- ▶ Petkova, Tarpey, Su and Ogden, (2016), Generated Effect Modifiers in randomized clinical trials," Biostatistics, 18, 105-118.
- ▶ Petkova, Park, Ciarleglio, Ogden and Tarpey (2020), Optimizing treatment decision rules through generated effect modifiers: A precision medicine tutorial," to appear British Journal of Psychiatry.
- ▶ Tarpey, Petkova and Zhu, (2016), Stratified Psychiatry via Convexity- Based Clustering with Applications Towards Moderator Analysis," Statistics and Its Interface, 9, 255-266.


Introduction



Method



Simulation Study



EMBARC



Discussion



Thank You!

Questions&Comments

